Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
US-2015010515-A1 · Jan 8, 2015 · US
Compositions and methods for treating bone diseases
US10500203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10500203-B2 |
| Application number | US-201615758083-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 23, 2016 |
| Priority date | Sep 9, 2015 |
| Publication date | Dec 10, 2019 |
| Grant date | Dec 10, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal deficiency, tarsal coalition or humeroradial synostosis.
First claim
Opening claim text (preview).
We claim: 1. A method for treating an orthopedic disease, comprising administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an inhibitor of beta-catenin signaling, wherein the orthopedic disease is fibular hemimelia. 2. The method of claim 1 , wherein the composition is administered in-utero. 3. The method of claim 2 , wherein the composition is administered in the third trimester of pregnancy. 4. The method of claim 1 , wherein the composition is administered after birth of the subject. 5. The method of claim 1 , wherein the subject is a subject having an elevated level of beta-catenin signaling. 6. The method of claim 1 , wherein the inhibitor of beta-catenin signaling is selected from the group consisting of LGK-974, IWP-2, iCRT 3, iCRT 14, ICG 001, XAV-939, KY02111, and a combination of at least two thereof. 7. The method of claim 6 , wherein the inhibitor of β-catenin signaling is iCRT 14. 8. The method of claim 6 , wherein the inhibitor of β-catenin signaling is XAV-939. 9. The method of claim 6 , wherein the inhibitor of β-catenin signaling is LGK-974. 10. The method of claim 6 , wherein the inhibitor of β-catenin signaling is iCRT 3. 11. The method of claim 6 , wherein the inhibitor of β-catenin signaling is IWP-2. 12. The method of claim 6 , wherein the inhibitor of β-catenin signaling is ICG 001. 13. The method of claim 6 , wherein the inhibitor of β-catenin signaling is KY02111.
Assignees
Inventors
Classifications
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Preparations for testing in vivo · CPC title
Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title
not condensed and containing further heterocyclic rings · CPC title
Knock-out vertebrates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10500203B2 cover?
- Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal deficiency, tarsal coalition or humeroradial synostosis.
- Who is the assignee on this patent?
- Univ Rush Medical Center
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).